Impact Events
MoreDate | Lead Company | Event | Type | Approval Change | Approval Likelihood |
---|---|---|---|---|---|
3/10/25 | Mineralys (MLYS) | Lorundrostat for Hypertension (Systemic) | Subscribers Only | Subscribers Only | Subscribers Only |
3/10/25 | Mineralys (MLYS) | Lorundrostat for Hypertension (Systemic) | Subscribers Only | Subscribers Only | Subscribers Only |
3/6/25 | ITM | EndolucinBeta for Neuroendocrine Tumors (NET) | Subscribers Only | Subscribers Only | Subscribers Only |
3/6/25 | Medicus Pharma (MDCX) | D-MNA for Skin Cancer - Basal Cell Carcinoma (BCC) | Subscribers Only | Subscribers Only | Subscribers Only |
3/3/25 | Biomed | NA-921 for Rett Syndrome | Subscribers Only | Subscribers Only | Subscribers Only |
Upcoming Catalysts
MoreExpected Date Range | Lead Company | Drug | Expected Catalyst |
---|---|---|---|
12/31/2024 | Subscribers Only | Subscribers Only | Regulatory - IND/CTA Filing |
02/12/2025 | Subscribers Only | Subscribers Only | Company - Analyst/R&D Update |
02/12/2025 | Subscribers Only | Subscribers Only | Trial Data - Updated Results |
02/27/2025 | Subscribers Only | Subscribers Only | Company - Analyst/R&D Update |
03/05/2025 | Subscribers Only | Subscribers Only | Company - Analyst/R&D Update |